Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream

The purpose of this narrative review is to provide a summary of the clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) to grant providers an understanding of which patients will benefit most from this novel topical antiandrogen medication. Clascoterone 1% cream (Winlevi) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Carol, Keri, Jonette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297041/
https://www.ncbi.nlm.nih.gov/pubmed/35874458
http://dx.doi.org/10.2147/CCID.S289750
_version_ 1784750396092186624
author Sanchez, Carol
Keri, Jonette
author_facet Sanchez, Carol
Keri, Jonette
author_sort Sanchez, Carol
collection PubMed
description The purpose of this narrative review is to provide a summary of the clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) to grant providers an understanding of which patients will benefit most from this novel topical antiandrogen medication. Clascoterone 1% cream (Winlevi) offers a new and exciting treatment approach for a difficult and common skin condition such as acne vulgaris. This topical androgen antagonist is the first of its kind but will hopefully provoke investigations into other androgen receptor antagonists with similar or better efficacy.
format Online
Article
Text
id pubmed-9297041
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92970412022-07-21 Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream Sanchez, Carol Keri, Jonette Clin Cosmet Investig Dermatol Review The purpose of this narrative review is to provide a summary of the clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) to grant providers an understanding of which patients will benefit most from this novel topical antiandrogen medication. Clascoterone 1% cream (Winlevi) offers a new and exciting treatment approach for a difficult and common skin condition such as acne vulgaris. This topical androgen antagonist is the first of its kind but will hopefully provoke investigations into other androgen receptor antagonists with similar or better efficacy. Dove 2022-07-15 /pmc/articles/PMC9297041/ /pubmed/35874458 http://dx.doi.org/10.2147/CCID.S289750 Text en © 2022 Sanchez and Keri. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Sanchez, Carol
Keri, Jonette
Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
title Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
title_full Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
title_fullStr Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
title_full_unstemmed Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
title_short Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
title_sort androgen receptor inhibitors in the treatment of acne vulgaris: efficacy and safety profiles of clascoterone 1% cream
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297041/
https://www.ncbi.nlm.nih.gov/pubmed/35874458
http://dx.doi.org/10.2147/CCID.S289750
work_keys_str_mv AT sanchezcarol androgenreceptorinhibitorsinthetreatmentofacnevulgarisefficacyandsafetyprofilesofclascoterone1cream
AT kerijonette androgenreceptorinhibitorsinthetreatmentofacnevulgarisefficacyandsafetyprofilesofclascoterone1cream

Ejemplares similares